ClinicalTrials.gg
TerminatedNCT04869943ARTESTUpdated Jan 26, 2024

Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

A Phase 3 interventional study of Enobosarm and Exemestane in Metastatic Breast Cancer, sponsored by Veru Inc.. Terminated at 54 sites in 4 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-01-26.

Sponsored by Veru Inc. · Phase 3, Interventional, and Treatment

Why this study was terminated
Business decision

From the registry’s dates

  • Primary completion was Jan 2024, 2 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Study summary

To demonstrate the efficacy of enobosarmin the treatment of androgen receptor positive (AR+) and estrogen receptor positive (ER+) metastatic breast cancer (MBC) as measured by radiographic progression free survival (rPFS).

Read the detailed description

This study is a multicenter, randomized, open-label, two treatment arm, efficacy and safety study, comprised of two sections, the main study and the post-study extension period. Subjects will be randomized to the two treatment arms in a 1:1 fashion (into the main study), with the opportunity for subjects initially randomized to the Control Treatment Group to cross over to receive the investigational treatment in the post-study extension period.

The primary efficacy endpoint of the study will be the median rPFS. Subjects will continue study treatment until disease progression confirmed by blinded independent central reader (BICR) is observed. A safety follow up visit will occur approximately 30 days after last dose of study drug. Thereafter, survival follow up will be completed monthly for one year. Survival follow up may be completed by phone or records review. After one year, survival follow up will be completed every 90 days.

After radiographic progression (by RECIST 1.1) is confirmed by blinded independent central reader (BICR) and have received approval from Medical Monitor, subjects in the Control Treatment Group may be crossed over to receive enobosarm treatment (9mg per day). Treatment will continue in this population (Enobosarm Post-study Group (EPG)) until radiographic progression (by RECIST 1.1), confirmed by BICR, is observed. The efficacy database for this crossover group will be completely separate from the main portion of the study and the data will be analyzed separately.

02

Conditions studied

  • Metastatic Breast Cancer

Keywords

  • Third line
  • 3rd line
  • Androgen Receptor
03

In context

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

This study's enrollment of 52 is below the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Veru Inc. is the lead sponsor of 12 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 3 (33%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide
  • Be able to communicate effectively with the study personnel
  • Aged ≥18 years
  • For Female Subjects

    • Menopausal status
  • Be as defined by the National Comprehensive Cancer Network as either:

    • Age ≥55 years and one year or more of amenorrhea
    • Age \<55 years and one year or more of amenorrhea, with an estradiol assay \<20 pg/mL
    • Age \<55 years and surgical menopause with bilateral oophorectomy
  • Be premenopausal or perimenopausal on ovarian suppression with LHRH agonist for at least 4 months, with an estradiol assay \<20 pg/mL and a negative urine pregnancy test.
  • If subject is of child bearing potential, the subject must agree to use acceptable methods of :

    • If female study participant could become pregnant, use acceptable methods of contraception from the time of the first administration of study medication until 6 months following administration of the last dose of study medication. Acceptable methods of contraception are as follows: Condom with spermicidal foam/gel/film/cream/suppository [i.e., barrier method of contraception], surgical sterilization of male partner (vasectomy with documentation of azoospermia) and a barrier method {condom used with spermicidal foam/gel/film/cream/suppository}
    • If female study participant has undergone documented tubal ligation (female sterilization), a barrier method (condom used with spermicidal foam/gel/film/cream/suppository) should also be used
    • If female study participant has undergone documented placement of an intrauterine device (IUD) or intrauterine system (IUS), a barrier method (condom with spermicidal foam/gel/film/cream/suppository) should also be used
  • For Male Subjects

    • Subject must agree to use acceptable methods of contraception:
  • If the study subject's partner could become pregnant, use acceptable methods of contraception from the time of the first administration of study medication until 6 months following administration of the last dose of study medication. Acceptable methods of contraception are as follows: Condom with spermicidal foam/gel/ film/cream/suppository [i.e., barrier method of contraception], surgical sterilization (vasectomy with documentation of azoospermia) and a barrier method {condom used with spermicidal foam/gel/film/cream/suppository}, the female partner uses oral contraceptives (combination estrogen/progesterone pills), injectable progesterone or subdermal implants and a barrier method (condom used with spermicidal foam/gel/film/cream/suppository)
  • If female partner of a study subject has undergone documented tubal ligation (female sterilization), a barrier method (condom used with spermicidal foam/gel/film/cream/suppository) should also be used
  • If female partner of a study subject has undergone documented placement of an intrauterine device (IUD) or intrauterine system (IUS), a barrier method (condom with spermicidal foam/gel/film/cream/suppository) should also be used
  • (ECOG) performance status of ≤2
  • Documented evidence of ER+/- breast cancer
  • is required as per 1.1 (NOTE: Bone only metastatic disease is acceptable but requires a measurable component
  • Have androgen receptor nuclei staining ≥40% as assessed by central laboratory
  • Received at least 2 in MBC setting which must have included both an AI (monotherapy or combination) and fulvestrant (monotherapy or combination); at least one must have been given in combination with a CDK 4/6 inhibitor.
  • Previously responded (without disease progression for at least 6 months) to one of the following treatments: fulvestrant monotherapy or fulvestrant plus CDK 4/6 inhibitor or nonsteroidal aromatase inhibitor monotherapy or nonsteroidal aromatase inhibitor plus CDK 4/6 inhibitor for metastatic breast cancer.
  • Subject is willing to comply with the requirements of the protocol through the end of the study

Exclusion criteria

Exclusion Criteria:

  • Known or allergy to enobosarm
  • (ALT) or aspartate aminotransferase (AST) >2.5 X (ULN) or total >ULN (an elevated total bilirubin up to 1.5 X ULN attributed to a previously confirmed diagnosis of Gilbert's disease is acceptable if all other eligibility criteria are met). In patients with documented to the liver, the limits for inclusion are ALT or AST >5.0 X ULN or total bilirubin >1.5 X ULN.
  • Patients with biliary catheter.
  • \< 30 mL/min as measured using the Cockcoft Gault formula (patients with mild and moderate renal failure are not excluded from participation in this study)
  • Previously received >1 course of systemic chemotherapy (not including immunotherapies or targeted therapies) for the treatment of metastatic breast cancer.

Note: Subjects may have received 1 course of chemotherapy in the or neoadjuvant setting would not count as a .

  • Subjects with radiographic evidence of central nervous system (CNS) metastases as assessed by CT or MRI that are not well-controlled (symptomatic or requiring control with continuous therapy [e.g., dexamethasone]) Note: Subjects with are permitted to participate in the study if the CNS metastases are medically well-controlled and stable for at least 30 days after receiving local therapy (irradiation, surgery, etc.)
  • Radiotherapy within 14 days prior to randomization except in case of localized radiotherapy for analgesic purpose or for lytic lesions at risk of fracture, which can then be completed within 7 days prior to randomization. Subjects must have recovered from radiotherapy toxicities prior to randomization
  • Any comorbid disease or condition (medical or surgical) which might compromise the hematologic, cardiovascular, endocrine, pulmonary, severe renal impairment, gastrointestinal, hepatic, or central nervous system; or other conditions that may interfere with the absorption, distribution, metabolism or excretion of study drug, or would place the subject at increased risk
  • Treatment with any product within \< 4 half-lives for each individual investigational product OR within 30 days prior to randomization
  • Major surgery within 30 days prior to randomization
  • Treatment with testosterone, methyltestosterone, oxandrolone (Oxandrin®), oxymetholone, danazol, fluoxymesterone (Halotestin®), testosterone-like agents (such as dehydroepiandrosterone, androstenedione, and other androgenic compounds, including herbals), or antiandrogens (enzalutamide, abiraterone, bicalutamide, apalutamide, or darolutamide). Previous therapy with testosterone and testosterone-like agents is acceptable with a 30-day washout (if previous testosterone therapy was long term depot within the past 6 months, the site should contact the Medical Monitor) or any other androgenic agent.
  • Treatment with any of the following hormone replacement therapies for metastatic breast cancer. Prior use in the adjuvant or neoadjuvant setting is allowed if the treatment is, discontinued greater than 30 days prior to randomization

    • Estrogens
    • Megesterol acetate
    • Testosterone
  • All other concurrent anticancer treatments (including, but not limited to, all SERMs unless randomized to the Control Treatment Group with a SERM as the control treatment, AIs unless randomized to Control Treatment Group (exemestane or exemestane plus everolimus) with the AI containing treatment as the control treatment, and all CDK 4/6 inhibitors)
  • An abnormal result which, based on the investigator's clinical judgment, would place the subject at increased risk
  • Has a known additional, invasive, that is progressing or required active treatment in the last 5 years [note: subjects with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, ductal breast carcinoma in situ, bladder cancer (superficial treated), or cervical carcinoma in situ that have undergone potentially curative therapy are not excluded]
  • Pregnant, lactating, or breastfeeding, or intending to become pregnant during the study or within 60 days after the final dose of study treatment
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Enobosarm Treatment Group

    Subjects in the Enobosarm Treatment Group will receive enobosarm 9mg each day by mouth until disease progression or an unacceptable adverse event is observed. The total duration of the study for a subject in the study from screening to follow-up visit is not standardized and will be different for each subject.

    Drug: Enobosarm

  • Active comparator
    Control Treatment Group

    Subjects in the Control Treatment Group will receive an ER targeted therapy limited to exemestane monotherapy, exemestane plus everolimus or selective estrogen receptor modulator (SERM) approved for the treatment of breast cancer and is part of the standard of care at the clinical study site. The decision of which comparator treatment will be used will be made prior to randomization. After radiographic progression, subjects randomized to the Control Treatment Group may be crossed over to receive enobosarm 9mg.

    Drug: Exemestane

Interventions

  • Oral Enobosarm 9mg per day

    Also known as: VERU-024

  • Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator (SERM)

    Also known as: Mestane

06

What researchers measure

Primary outcomes

  1. To demonstrate the efficacy of Enobosarm in the treatment of androgen receptor positive (AR+) and estrogen receptor positive (ER+) metastatic breast cancer (MBC) as measured by radiographic progression free survival (rPFS).

    The primary endpoint for the study is the median radiographic progression free survival (rPFS) in the Enobosarm Treatment Group compared to the Control Treatment Group. Progression will be defined based on RECIST 1.1.

    Time frame: Day 120

Secondary outcomes

  1. Objective Response Rate (ORR)

    Objective Response Rate (ORR), proportion of subjects with a best tumor response of ORR (PR or CR) on study

    Time frame: Day 180

07

Study locations

54 sites
  • Ironwood Cancer and Research Centers
    Chandler, Arizona 85224, United States
  • Banner Health/ Banner MD Anderson Cancer Center
    Gilbert, Arizona 85234, United States
  • The Oncology Insitute of Hope and Innovation
    Glendale, California 91204, United States
  • Marin Cancer Care, Inc.
    Greenbrae, California 94904, United States
  • California Research Institute (CRI)
    Los Angeles, California 90027, United States
  • University of California San Francisco Comprehensive Cancer Center
    San Francisco, California 94158, United States
  • Providence Medical Group
    Santa Rosa, California 95043, United States
  • Rocky Mountain Cancer Centers
    Denver, Colorado 81008, United States
  • Morton Plant Hospital/ BayCare Health System, Inc
    Clearwater, Florida 33756, United States
  • University of Miami- Sylvester Comprehensive Cancer Center
    Miami, Florida 33146, United States
  • Miami Cancer Institute
    Miami, Florida 33176, United States
  • Woodlands Medical Specialists, PA
    Pensacola, Florida 32503, United States
  • Miami Cancer Institute, Plantation MCIP
    Plantation, Florida 33324, United States
  • University Cancer & Blood Center
    Athens, Georgia 30607, United States
  • Blessing Corporate Services
    Quincy, Illinois 62301, United States
  • MBCCOP - LSU Health Sciences Center
    Shreveport, Louisiana 71103, United States
  • Dana-Farber Cancer Institute Breast Oncology
    Boston, Massachusetts 02215, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • Astera Cancer Care
    East Brunswick, New Jersey 08816, United States
  • Inspira Medical Center Mullica Hill
    Mullica Hill, New Jersey 08062, United States
  • Inspira Medical Center
    Vineland, New Jersey 08360, United States
  • The Lindner Center for Research and Education at the Christ Hospital
    Cincinnati, Ohio 45219, United States
  • Magee-Women's Hospital
    Pittsburgh, Pennsylvania 15219, United States
  • Tidelands Health
    Murrells Inlet, South Carolina 29576, United States
  • Tennessee Cancer Specialists
    Knoxville, Tennessee 37909, United States
  • Baptist Clinical Research Institute
    Nashville, Tennessee 38102, United States
  • Texas Oncology Sammons Cancer Center
    Dallas, Texas 75246, United States
  • Texas Oncology - Tyler
    Tyler, Texas 75702, United States
  • Virginia Cancer Specialists
    Fairfax, Virginia 22031, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • Oncology and Hematology Associates of Southwest Virginia, Inc.
    Roanoke, Virginia 24014, United States
  • MultiCare Institute for Research and Innovation
    Puyallup, Washington 98372, United States
  • Cancer Care Northwest
    Spokane, Washington 99216, United States
  • MultiCare Institute for Research and Innovation
    Spokane, Washington 99218, United States
  • Centrum Onkologii Ziemi Lubelskiej im. św. Jana z Dukli
    Lublin, 20-090, Poland
  • Specjalistyczny Szpital Onkologiczny NU-MED
    Maków Mazowiecki, 97-200, Poland
  • "Oddział Onkologii Klinicznej i Chemioterapii Europejskie Centrum Zdrowia Otwock"
    Otwock, 05-400, Poland
  • Klinika Nowotworów Piersi i Chirurgii Rekonstrukcyjnej, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy
    Warsaw, 02-781, Poland
  • Wojewódzka Przychodnia Onkologiczna, Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Łodzi
    Łódź, 91-211, Poland
  • Instytut Centrum Zdrowia Matki Polki
    Łódź, 93-338, Poland
  • A Coruña University Hospital
    A Coruña, Spain
  • Hospital Universitari Dexeus
    Barcelona, 08028, Spain
  • Hospital Universitari Vall d'Hebron - Vall d'Hebron Institut d'Oncologia (VHIO)
    Barcelona, 08035, Spain
  • Institut Catala d'Oncologia (ICO)
    Barcelona, 08908, Spain
  • Hospital Universitari Arnau de Vilanova de Lleida
    Lleida, 25198, Spain
  • Hospital Ruber Internacional
    Madrid, 28034, Spain
  • Hospital Universitario 12 de Octubre (H12O)
    Madrid, 28041, Spain
  • Hospital Universitario HM Sanchinarro
    Madrid, 28050, Spain
  • Hospital Clínico Universitario de Valencia (CHUV)
    Valencia, 46010, Spain
  • Municipal Institution "Dnipropetrovsk City Multi-field Clinical Hospital #4", Dnepropetrovsk state m
    Dnepropetrovsk, 49000, Ukraine
  • State institution "V.T. Zaycev Institute of general and urgent surgery of National academy medical sciences of Ukraine"
    Kharkiv, 61103, Ukraine
  • Khmelnytsky Regional Antitumor Center, Department of Breast, Skin, Soft Tissues and Bones Tumorsa
    Khmelnytskyi, 29000, Ukraine
  • Kyiv City Clinical Oncology Center
    Kyiv, 03115, Ukraine
  • Odessa Regional Oncological Dispensary
    Odessa, 65000, Ukraine
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Jan 2024, 26 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2021
First posted
May 3, 2021
StartActual
Oct 12, 2021
Primary completionActual
Jan 9, 2024
CompletionActual
Jan 9, 2024
Last update
Jan 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04869943
Lead sponsor
Veru Inc.
Responsible party
Sponsor
First posted
May 3, 2021
Start date
Oct 12, 2021
Primary completion
Jan 9, 2024
Completion
Jan 9, 2024
Last update
Jan 26, 2024

Study contacts

Barnette
study chair · Veru Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ostarine

Start the discussion